The biopharma buffer market is estimated to be valued at US$ 3.44 Bn in 2022 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Biopharma buffers are solutions used to maintain a stable pH level in biopharmaceutical manufacturing and storage processes. They help control pH by neutralizing acids or bases that may be produced during reactions or formulations. Common buffers used in biopharma production include phosphate, Tris, and acetate buffers. They are employed extensively across upstream and downstream bioprocessing as well as purification, fill-finish, and storage of biologics. Rising demand for monoclonal antibodies, recombinant proteins, and other biologics has scaled up biopharma manufacturing activities globally in recent years.
The biopharma buffer market is driven by increasing production of biopharmaceutical drugs and stringent regulatory guidelines for buffer selection and validation. Massive investment in biomanufacturing capacity expansion especially in Asia Pacific and rest of world regions is propelling buffer demand. Moreover, implementation of process analytical technology (PAT) by regulatory agencies has increased buffer testing and characterization requirements during drug development and manufacturing, thereby fueling market growth. Stringent ICH and FDA guidelines mandate characterization of buffer components, validation of buffer preparation methods, and documentation of any changes made to buffers. This necessitates frequent replacement of buffers and adoption of qualified vendor supply chains by biopharma companies.
Strength: The biopharma buffer market has experienced significant growth in recent years owing to rising demand for biopharmaceuticals. Biopharma buffers ensure stability and aid in purification of biologics. Key players have made heavy investments in R&D to develop effective and compliant buffers.
Weakness: High costs associated with formulation and production of biopharma buffers remains a weakness. Fluctuations in raw material prices pose challenges. Dependence on a few suppliers increases the risk of supply chain disruptions.
Opportunity: Increasing adoption of monoclonal antibodies and recombinant proteins as therapeutic agents offer lucrative opportunities. Growing biosimilars market in developing nations present new opportunities. Additionally, adoption of single-use technologies will augment demand.
Threats: Stringent regulatory norms and compliance issues pose threats. Risk of contamination remains a concern. Substitution threat from alternate purification methods can hamper growth prospects.
The Global Biopharma Buffer Market Growth is expected to witness high, exhibiting CAGR of 7.1% over the forecast period, due to increasing adoption of biologic therapeutics. Rising demand for monoclonal antibody-based drugs and recombinant vaccines will propel market revenue.
Regional analysis: North America dominates the global market and is expected to maintain its lead. Advancements in biopharmaceutical R&D coupled with presence of major players drives the North America market. Asia Pacific market is anticipated to witness fastest growth owing to expanding biopharma industry, increasing disposable incomes, and growing health awareness in the region.
Key players: Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation. Players focus on new product launches, partnerships and expansion strategies to strengthen their foothold.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it